WASHINGTON, D.C. - The U.S. Supreme Court on Oct. 7 asked the U.S. Solicitor General to weigh in on what standard should be used to adequately plead claims about off-label marketing of a heartburn drug under the False Claims Act (United States of America, ex rel. Noah Nathan v. Takeda Pharmaceuticals North America, Inc., et al., No. 12-1349, U.S. Sup.).